Biokin Secures Record $250 Million Milestone Payment in Partnership with BMS, Marking a Turning Point for China’s Innovative Pharma Sector
Thursday, October 23, 2025
Biokin, a rapidly rising multinational pharmaceutical company from China, has achieved a landmark $250 million milestone payment from its partnership with the global pharmaceutical giant Bristol Myers Squibb (BMS), cementing its place at the forefront of Asia’s burgeoning biopharmaceutical sector. This achievement stands as the largest milestone disbursement ever for an antibody-drug conjugate (ADC) among Chinese out-licensing deals, and it signals a dramatic shift in both the scale and strategic influence of the region's innovative drug landscape.
The deal, forged in October 2025, follows an extraordinary $800 million upfront payment received at the start of the year and further validates Biokin’s lead program, iza-bren, an EGFR×HER3 bispecific ADC. This blockbuster agreement pushes the total potential value of BMS and Biokin’s global co-development and commercialization collaboration to a staggering $8.4 billion, highlighting the growing appetite among Western firms for access to China’s innovation engine as they navigate looming patent cliffs and seek new growth vectors within the ADC space.
Biokin’s trajectory is emblematic of China’s surging reputation as a source of first-in-class novel molecules. At both the 2025 World Congress on Lung Cancer and the recent ESMO Congress in Europe, iza-bren demonstrated strong efficacy results, with its domestic Phase III trial for nasopharyngeal carcinoma yielding a twofold improvement over key clinical endpoints. These pivotal clinical data have captured attention from leading oncologists globally, with MD Anderson’s representatives publicly expressing eagerness for a US launch, a scenario rarely seen for China-developed drugs. Further recognition for the program’s progress comes in the form of multiple ‘Breakthrough Therapy’ designations from regulators in China and the US, underscoring governments’ intent to accelerate access to innovative cancer therapies.
The origins of Biokin’s success reflect a bold long-term strategic vision developed by founder Zhu Yi, who transitioned the organization from a generics manufacturer to an innovation-focused biotech over a decade ago. Zhu established a lean scientific hub in Seattle, allowing early-stage US R&D, while leveraging China’s efficient regulatory climate, expansive engineering talent pool, and robust patient recruitment capabilities for rapid clinical and commercial scalability. Unlike most local peers, Biokin also negotiated to retain significant international R&D and commercialization rights, cementing its aspiration to become a true global multinational growth story within five years. As a result, its market valuation on the Chinese mainland has soared fifteen-fold in just over two years, and the company has emerged as a new darling among Hong Kong investors eager for biopharma innovation exposure.
Biokin’s pipeline has expanded beyond iza-bren, with its second ADC, T-bren, also posting promising results in Phase III trials targeting widespread cancers such as lung, gastric, and breast malignancies, and with the firm’s first antibody–radionuclide conjugate (ARC) recently entering clinical development following China CDE approval. Altogether, more than 40 clinical studies—ten of them pivotal Phase III registration trials in China and three globally—attest to Biokin’s maturing innovation engine and its capacity to repeatedly deliver credible candidates to late-stage development. The company expects to launch iza-bren commercially, first in China in 2026, outpacing its projected US approval by three years and asserting Asian regulatory and clinical frameworks' increasing sophistication and global influence.
Ultimately, Biokin’s record-setting milestone from BMS is far more than a financial headline. It signals a new era not only for the company, but for China’s overall biopharmaceutical ecosystem—a sector now able to forge partnerships and set benchmarks on equal footing with established Western players. The Asia region, long viewed as a manufacturing hub or market for Western pharmaceuticals, is fast becoming an integral driver of next-generation drug R&D, licensing economics, and multinational pipeline strategy.
